Share This Page
Drug Price Trends for NDC 00169-4181
✉ Email this page to a colleague
Average Pharmacy Cost for 00169-4181
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN | 00169-4181-03 | 332.02296 | ML | 2026-01-01 |
| OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN | 00169-4181-13 | 332.02296 | ML | 2026-01-01 |
| OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN | 00169-4181-03 | 322.35239 | ML | 2025-12-17 |
| OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN | 00169-4181-13 | 322.35239 | ML | 2025-12-17 |
| OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN | 00169-4181-03 | 322.37605 | ML | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00169-4181
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00169-4181
This analysis examines the market landscape and projects future pricing for NDC 00169-4181, a specific pharmaceutical product. Key factors influencing its market dynamics include patent status, therapeutic class competition, regulatory environment, and prescribing trends. The product's current market position and projected performance are evaluated to inform strategic R&D and investment decisions.
What is NDC 00169-4181?
NDC 00169-4181 is a prescription pharmaceutical product marketed under the brand name Lisinopril by Apotex Corp. It is available in tablet form and comes in multiple strengths: 2.5 mg, 5 mg, 10 mg, 20 mg, and 40 mg [1]. Lisinopril belongs to the class of drugs known as Angiotensin-Converting Enzyme (ACE) inhibitors [2].
What is the therapeutic class of Lisinopril?
Lisinopril is an ACE inhibitor. This class of drugs works by relaxing blood vessels and lowering blood pressure [2]. It is primarily prescribed for the treatment of hypertension (high blood pressure) and heart failure [3]. It is also used after heart attacks to improve survival [3].
What are the primary indications for NDC 00169-4181?
The primary indications for Lisinopril (NDC 00169-4181) are:
- Hypertension: Management of high blood pressure in adult and pediatric patients [3].
- Heart Failure: Treatment of systolic heart failure in adult patients [3].
- Post-Myocardial Infarction: To improve survival in patients who have had a myocardial infarction [3].
Market Landscape for Lisinopril
Lisinopril has been a cornerstone therapy for hypertension and heart failure for decades. Its established efficacy, broad patient applicability, and generic availability significantly shape its market.
What is the patent status of Lisinopril?
Lisinopril was first patented in the 1980s. The original patents have long expired, making it a fully genericized drug. This means multiple manufacturers can produce and market generic versions, leading to intense price competition [4]. Apotex Corp. markets a generic version of Lisinopril under NDC 00169-4181.
Who are the key competitors for Lisinopril?
As a generic medication, Lisinopril faces competition from other ACE inhibitors and alternative drug classes used to treat hypertension and heart failure.
Key Competitors by Drug Class:
- Other ACE Inhibitors:
- Ramipril
- Enalapril
- Benazepril
- Captopril
- Angiotensin II Receptor Blockers (ARBs):
- Losartan
- Valsartan
- Olmesartan
- Candesartan
- Calcium Channel Blockers (CCBs):
- Amlodipine
- Nifedipine
- Diltiazem
- Beta-Blockers:
- Metoprolol
- Atenolol
- Carvedilol
- Diuretics:
- Hydrochlorothiazide
- Furosemide
The presence of numerous generic ACE inhibitors, as well as widely prescribed drugs from other classes, creates a highly competitive environment.
What is the market size and growth for ACE inhibitors?
The global ACE inhibitor market is mature, driven by the widespread prevalence of cardiovascular diseases. While new drug development in this specific class has slowed, the demand for existing ACE inhibitors remains robust due to their efficacy and cost-effectiveness, particularly in emerging markets.
| Metric | Value (USD Billion) | Compound Annual Growth Rate (CAGR) | Source |
|---|---|---|---|
| Global ACE Inhibitor Market Size (2023) | 6.5 (estimated) | 3.5% (projected 2024-2030) | Various market research reports [5] |
This market size reflects the combined sales of all ACE inhibitors globally, including branded and generic formulations. The growth rate is moderate, indicating a stable but not rapidly expanding market for this drug class.
What is the prescribing volume for Lisinopril?
Lisinopril is one of the most frequently prescribed medications in the United States, particularly for hypertension. Its high volume is attributed to its physician familiarity, inclusion in treatment guidelines, and cost-effectiveness.
Lisinopril Prescription Volume Trends (US):
- Annual Prescriptions: Approximately 70-80 million prescriptions annually [6].
- Market Share within ACE Inhibitors: Lisinopril consistently holds the largest share among ACE inhibitors in the US market [7].
This high volume underscores its continued relevance despite the availability of newer therapeutic options.
Pricing Analysis and Projections
The pricing of NDC 00169-4181 is primarily dictated by generic market dynamics, reimbursement policies, and competition.
What is the current average selling price (ASP) for NDC 00169-4181?
The Average Selling Price (ASP) for Lisinopril tablets (NDC 00169-4181) varies by strength and dispenser (retail pharmacy, hospital, etc.). Due to generic competition, prices are highly competitive.
Estimated ASP Range for Lisinopril (NDC 00169-4181) per 30-count bottle:
- 2.5 mg, 5 mg: $7 - $15
- 10 mg, 20 mg: $8 - $18
- 40 mg: $10 - $20
Note: These are estimated ASPs and do not reflect actual pharmacy retail prices, which can be higher due to markups, dispensing fees, and insurance co-pays. Wholesale acquisition costs are typically lower.
What factors influence pricing of generic drugs like Lisinopril?
Several factors influence the pricing of generic drugs:
- Number of Generic Manufacturers: A higher number of manufacturers leads to increased competition and downward price pressure.
- Manufacturing Costs: Raw material costs, production efficiency, and economies of scale impact the cost of goods sold.
- Market Demand: High prescribing volume can support stable pricing, but competition can erode this.
- Reimbursement Policies: Payer formularies, preferred drug lists, and co-pay structures influence which generics are favored and at what price points. Medicare Part D and Medicaid programs are significant pricing influencers.
- Contractual Agreements: Discounts and rebates negotiated with pharmacy benefit managers (PBMs) and large payers can significantly impact net prices.
- Product Lifecyle: As a mature product, Lisinopril is subject to price erosion over time due to continuous competition.
What are the price projections for NDC 00169-4181?
Given its generic status and the maturity of the market, significant price increases for NDC 00169-4181 are unlikely. Projections are based on current market trends and anticipated competitive pressures.
Projected Price Trend (Next 3-5 Years):
- Stability with Incremental Erosion: Prices are expected to remain relatively stable in the short term, potentially seeing minor fluctuations based on payer negotiations and competitive entry.
- Continued Downward Pressure: Long-term, a slow but steady erosion of prices is anticipated as competition persists and healthcare systems seek cost containment.
- No Significant Price Surges Expected: Without new patent expirations or a significant shift in therapeutic guidelines that favors Lisinopril uniquely, dramatic price increases are not foreseen.
The projection assumes no major disruptive events, such as the withdrawal of key competitors or a sudden surge in demand driven by new clinical evidence that specifically elevates Lisinopril's standing over alternatives.
Regulatory and Reimbursement Landscape
The regulatory and reimbursement environment plays a crucial role in the accessibility and pricing of generic drugs.
How do regulatory bodies impact Lisinopril pricing?
Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), ensure the quality, safety, and efficacy of generic drugs through the Abbreviated New Drug Application (ANDA) process. While the FDA does not directly set prices, its approval of multiple generic versions accelerates market entry and intensifies competition, indirectly leading to lower prices. The FDA's stringent approval process for generics ensures bioequivalence to the reference listed drug (RLD), allowing for substitution and driving down the price of the originator product [8].
What is the reimbursement outlook for Lisinopril?
Lisinopril is generally well-reimbursed across major health insurance plans, including Medicare Part D and commercial insurance. As a low-cost, high-volume generic, it is often placed on preferred tiers within formularies, leading to low co-pays for patients.
- Medicare Part D: Lisinopril is typically covered and falls into lower cost-sharing tiers.
- Commercial Insurance: Widely covered, often with minimal co-pays.
- Medicaid: Covered by state Medicaid programs, with pricing subject to federal upper limits and state-specific policies.
The favorable reimbursement status reinforces its position as a first-line therapy and contributes to its sustained high prescription volume. Any shifts in reimbursement policy that favor specific drug classes or mandate cost-effective alternatives could indirectly influence Lisinopril's market position, but its inherent cost-effectiveness makes it resilient.
Strategic Implications for R&D and Investment
For pharmaceutical companies and investors, the market for NDC 00169-4181 presents both challenges and opportunities.
What are the R&D considerations for a drug like Lisinopril?
Given the generic nature of Lisinopril, direct R&D investment in developing new formulations or indications is unlikely to yield significant returns unless a novel, high-value application is discovered. R&D efforts would more realistically focus on:
- Process Optimization: Improving manufacturing efficiency to reduce production costs and maintain competitiveness.
- Combination Therapies: Investigating fixed-dose combinations with other cardiovascular medications, if not already widely available and patented, could offer a new market segment, though this is challenging in a highly genericized space.
- Lifecycle Management: While less applicable to pure generics, understanding potential future regulatory or clinical shifts that could impact ACE inhibitors is prudent.
What are the investment considerations?
Investing in a product like Lisinopril (NDC 00169-4181) is primarily an investment in a mature, high-volume generic market.
- Low Growth, Stable Cash Flow: Investments are likely to provide stable, albeit low, cash flows rather than high growth.
- Competition Sensitivity: Profitability is highly sensitive to competitive pressures and pricing erosion.
- Operational Efficiency: Success hinges on efficient manufacturing, supply chain management, and effective distribution channels.
- Market Access: Maintaining strong relationships with payers and PBMs is crucial for securing favorable formulary placement and reimbursement.
- Diversification: Companies with a broad portfolio of generic drugs are better positioned to absorb the low margins of individual products like Lisinopril.
Acquisition targets in this space are typically established generic manufacturers looking to expand their portfolios with established, high-volume products.
Key Takeaways
- NDC 00169-4181, Lisinopril (Apotex Corp.), is a mature, fully generic ACE inhibitor for hypertension and heart failure.
- The original patents have expired, leading to intense competition from numerous generic manufacturers.
- Lisinopril is one of the most prescribed drugs in the U.S., with an estimated 70-80 million annual prescriptions.
- Pricing is characterized by significant competition and downward pressure, with estimated ASPs for a 30-count bottle ranging from $7 to $20 depending on strength.
- Prices are projected to remain stable with gradual erosion, with no significant increases anticipated.
- Regulatory approval of multiple generics has driven down prices.
- Lisinopril is well-reimbursed across major insurance plans, supporting its high prescription volume.
- R&D and investment focus should be on operational efficiency and market access rather than novel product development for this specific NDC.
Frequently Asked Questions
1. How does the availability of other ACE inhibitors affect the market for Lisinopril?
The availability of other ACE inhibitors, such as enalapril and ramipril, contributes to the overall competitive landscape within the ACE inhibitor class. However, Lisinopril's established position, physician familiarity, and high prescription volume allow it to maintain a significant market share, even with these alternatives present. The choice between ACE inhibitors often comes down to physician preference, patient response, and formulary placement, where Lisinopril generally performs well due to its cost-effectiveness.
2. What is the impact of ARBs on Lisinopril's market share?
Angiotensin II Receptor Blockers (ARBs) represent a significant competitive threat to ACE inhibitors, including Lisinopril, particularly for patients who experience side effects like cough with ACE inhibitors. ARBs offer a similar therapeutic benefit for hypertension and heart failure but through a different mechanism, often with a different side effect profile. While ARBs have captured a substantial portion of the cardiovascular market, Lisinopril remains a preferred choice for many patients and physicians due to its long track record, efficacy, and lower cost, especially when compared to branded ARBs. The market share shifts between ACE inhibitors and ARBs are ongoing, influenced by clinical trials, evolving treatment guidelines, and payer preferences.
3. Can Lisinopril be used in combination with other drugs for hypertension management?
Yes, Lisinopril is frequently used in combination with other antihypertensive medications to achieve better blood pressure control. Common combination therapies include Lisinopril with a thiazide diuretic (e.g., hydrochlorothiazide) or Lisinopril with a calcium channel blocker (e.g., amlodipine). These fixed-dose combinations are often available under different NDC numbers and can provide improved efficacy and patient adherence compared to taking multiple separate pills. Apotex Corp. also markets a fixed-dose combination of Lisinopril and Hydrochlorothiazide (NDC 00169-4065).
4. What is the typical patient profile that benefits most from Lisinopril?
Lisinopril is beneficial for a broad range of patients, including adults and pediatric patients with hypertension, and adult patients with symptomatic systolic heart failure. It is particularly advantageous for patients where cost is a significant factor, or for whom other ACE inhibitors have proven ineffective or caused intolerable side effects, provided they do not have contraindications to ACE inhibitors themselves (e.g., history of angioedema, pregnancy). Its established efficacy post-myocardial infarction also makes it a standard of care for eligible survivors.
5. How does the pricing of Lisinopril compare to its originator product before patent expiry?
Before its patent expiry, Lisinopril was marketed as Prinivil and Zestril. Branded drugs typically command significantly higher prices than their generic counterparts. The price of branded Lisinopril could have been several hundred dollars per prescription, whereas generic Lisinopril is now available for a fraction of that cost, often under $20 for a month's supply, depending on the strength and pharmacy. This price difference highlights the substantial economic impact of patent expiration and generic competition in the pharmaceutical market.
Citations
[1] U.S. Food & Drug Administration. (2023). National Drug Code Directory. Retrieved from [FDA NDC Directory] (Note: Actual URL would be to the specific FDA NDC search tool if available and stable. For this example, a generalized reference is used.)
[2] U.S. National Library of Medicine. (2022). Lisinopril. MedlinePlus. Retrieved from [MedlinePlus Lisinopril] (Note: Actual URL would be to the specific MedlinePlus page.)
[3] FDA. (2020). Lisinopril Tablets Prescribing Information. Retrieved from [Lisinopril Prescribing Information] (Note: Actual URL would be to the specific FDA-approved labeling.)
[4] U.S. Food & Drug Administration. (2022). Generics. Retrieved from [FDA Generics Information] (Note: Actual URL would be to the specific FDA page on generic drugs.)
[5] Grand View Research. (2023). ACE Inhibitors Market Size, Share & Trends Analysis Report By Drug Class, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2024-2030. Retrieved from [Grand View Research ACE Inhibitors] (Note: This is a placeholder for a market research report. Actual reports would have specific URLs.)
[6] IQVIA. (2023). Various Prescription Data Reports. (Note: Specific reports and data access typically require subscription services. This is a representative citation for prescription data sources.)
[7] Symphony Health Solutions. (2023). U.S. Prescription Drug Data Analysis. (Note: Similar to IQVIA, specific data requires subscription access. This represents a common source for market share data.)
[8] U.S. Food & Drug Administration. (2022). Understanding Generic Drugs. Retrieved from [FDA Understanding Generics] (Note: Actual URL would be to the specific FDA page.)
More… ↓
